- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03265353
Vascular Effects of Dietary Potassium
4. november 2020 opdateret af: University of Delaware
Vascular Effects of Dietary Potassium in Humans
The purpose of this study is to determine if dietary potassium can attenuate the deleterious effects of high sodium on blood vessel function in healthy, salt-resistant participants.
Studieoversigt
Status
Afsluttet
Betingelser
Detaljeret beskrivelse
Cardiovascular disease remains a major Public Health problem in the U.S. and is the result of diseases such as atherosclerosis and high blood pressure (BP).
Several dietary factors have been implicated as risk factors including high sodium and low potassium diets.
Indeed, it is well known that excess sodium can increase BP while potassium rich diets have BP lowering properties.
While the role of these two nutrients on BP is widely accepted, their impact on the vasculature has received less attention.
Endothelial dysfunction, characterized by impaired dilation is an important non-traditional risk factor for atherosclerosis.
Data in animal models suggest that salt loading, independent of changes in BP, results in endothelial dysfunction while evidence is mounting that potassium may be beneficial to vascular health.
Further, potassium may be more effective in the presence of high sodium however the role of potassium in protecting the vasculature from a high sodium diet in salt-resistant adults has not been explored.
A potential mechanism responsible for sodium induced vascular dysfunction is overproduction of reactive oxygen species resulting in reduced nitric oxide (NO) production/ bioavailability.
It has been suggested that potassium can counteract sodium's effect by reducing ROS.
The central hypothesis is that potassium can protect against the deleterious effects of high sodium on the vasculature by reducing oxidative stress and preserving NO.
In this grant, the investigators propose to use a 21-day controlled feeding study to compare the effects of a high sodium diet (300 mmol) combined with either a high (120 mmol) or moderate (65 mmol) amount of potassium and low sodium (50 mmol) combined with moderate potassium (crossover design, diet order sequence randomized) on 2 levels of the vasculature, conduit artery and microvasculature.
These experiments will be performed in salt-resistant participants to study the vascular effects alone, independent of changes in BP.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
47
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Delaware
-
Newark, Delaware, Forenede Stater, 19716
- University of Delaware
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
22 år til 45 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- healthy
- normal blood pressure
Exclusion Criteria:
- hypertension
- history of heart disease
- diabetes
- kidney disease
- obese (BMI ≥30)
- significant weight changes in the last 6 months
- use of tobacco products
- pregnant
- on a special diet (gluten free; vegan)
- take any medications for the above conditions
- endurance trained athletes
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Moderate Potassium/Low Sodium Diet
Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/low sodium diet.
|
7 days of the prescribed diet
|
|
Andet: Moderate Potassium/High Sodium Diet
Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/high sodium diet.
|
7 days of the prescribed diet
|
|
Andet: High Potassium/High Sodium Diet
Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the high potassium/high sodium diet.
|
7 days of the prescribed diet
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Conduit artery endothelial-dependent dilation
Tidsramme: on the 7th day of each diet
|
The change in flow-mediated dilation (FMD) between the 3 diets as assessed by brachial artery FMD
|
on the 7th day of each diet
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Arterial Stiffness
Tidsramme: on 7th day of each diet
|
Assessed by carotid to femoral artery pulse wave velocity
|
on 7th day of each diet
|
|
Wave reflection
Tidsramme: on 7th day of each diet
|
Assessed by augmentation index
|
on 7th day of each diet
|
|
Endothelial cell expression of oxidative stress marker
Tidsramme: on the 7th day of each diet
|
Assessed in venous endothelial cells from participants.
|
on the 7th day of each diet
|
|
Ambulatory blood pressure
Tidsramme: 7 days
|
Assessed by 24 hr ambulatory blood pressure monitoring.
|
7 days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
25. juli 2013
Primær færdiggørelse (Faktiske)
22. september 2019
Studieafslutning (Faktiske)
22. september 2019
Datoer for studieregistrering
Først indsendt
25. august 2017
Først indsendt, der opfyldte QC-kriterier
25. august 2017
Først opslået (Faktiske)
29. august 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
5. november 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
4. november 2020
Sidst verificeret
1. november 2020
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- 487998-8
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kardiovaskulær risikofaktor
-
Ottawa Hospital Research InstituteAfsluttetStress | Crisis Resource Management (CRM) færdigheder | Advanced Cardiovascular Life Support (ACLS) færdighederCanada
-
Pakistan Institute of Living and LearningAfsluttetPsykose | At Risk Mental State (ARMS)Pakistan
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)AfsluttetFørste episode psykose (FEP) | At Risk Mental State (ARMS)Forenede Stater
-
Cairo UniversityShaimaa Mostafa; Yasmin Zakaria; Ibrahim Fawzy; Mona Aboulghar; Mona FouadAfsluttet
-
Tanta UniversityAfsluttet
-
The First Affiliated Hospital of Soochow UniversityRekrutteringCore Binding Factor Akut Myeloid Leukæmi | KIT-mutationsrelaterede tumorerKina
-
Taipei Medical University WanFang HospitalAfsluttetParonychia | Epidermal Growth Factor Receptor InhibitorTaiwan
-
Chang Gung Memorial HospitalAfsluttetParonychia | Epidermal Growth Factor Receptor InhibitorTaiwan
-
D.O. Ott Research Institute of Obstetrics, Gynecology...Aktiv, ikke rekrutterendeInfertilitet | Chlamydia Trachomatis-infektion | Antichlamydia antistoffer | Tubal Factor InfertilitetDen Russiske Føderation
-
University Hospital, Strasbourg, FranceRekrutteringHæmoragiske lidelser | Ekstrinsisk Pathway Factor Deficiency | Hepatocellulær insufficiens med koagulopatiFrankrig
Kliniske forsøg med Moderate Potassium/Low Sodium Diet
-
Wake Forest University Health SciencesTrukket tilbageDyspepsi | KostændringerForenede Stater
-
Boston Children's HospitalIkke rekrutterer endnuGastrostomi | Forhåbning | Ernæringsbesvær
-
Warsaw University of Life SciencesAfsluttetTyndtarmsbakterieovervækst | SIBO | Bakterieovervækstsyndrom i tyndtarmen (SIBO)Polen
-
Cairo UniversityRekrutteringFedme | Irritabelt tarmsyndrom | Abdominal fedmeEgypten
-
University Hospital, RouenAfsluttet
-
Boston Children's HospitalRekrutteringGastrostomi | Forhåbning | ErnæringsbesværForenede Stater
-
University of BariAfsluttetFunktionelle gastrointestinale lidelser | IBSItalien
-
Gødstrup HospitalIkke rekrutterer endnuHøjt blodtryk | Natrium overskud | Dialyseafhængig kronisk nyresygdom | DialysepatienterDanmark
-
San Antonio Military Medical CenterAfsluttetFed leverForenede Stater
-
University Hospital, BordeauxAfsluttet